Adicet Bio Announces Major Stock Offering Agreement
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adicet Bio ( (ACET) ) just unveiled an update.
On October 7, 2025, Adicet Bio, Inc. entered into an Underwriting Agreement with Jefferies LLC and Guggenheim Securities, LLC for a registered direct offering of 70,001,000 shares of common stock and pre-funded warrants for 10,000,000 shares. The shares are priced at $1.00 each, while the pre-funded warrants are priced at $0.9999 per share, with an underwriting discount of 6%. The company expects net proceeds of approximately $74.8 million from the offering, which is anticipated to close on October 8, 2025.
The most recent analyst rating on (ACET) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.
Spark’s Take on ACET Stock
According to Spark, TipRanks’ AI Analyst, ACET is a Underperform.
Adicet Bio faces significant financial challenges and technical weaknesses, with no revenue and ongoing losses as critical concerns. The poor valuation further impacts the stock’s appeal. While the new board appointment is positive, it does not mitigate the substantial risks present in the company’s financials and market performance.
To see Spark’s full report on ACET stock, click here.
More about Adicet Bio
Average Trading Volume: 502,737
Technical Sentiment Signal: Hold
Current Market Cap: $83.25M
See more insights into ACET stock on TipRanks’ Stock Analysis page.
